Abstract: The present invention discloses an ionic liquid composition comprising an at least partially hydrophobic ionic liquid, wherein the at least partially hydrophobic ionic liquid comprises a di cation comprising two monocationic groups linked by a bridging group wherein the bridging group provides an at least partially hydrophobic character. The composition may also include a hydrophilic ionic liquid. The hydrophobic ionic liquid may include a quaternary ammonium group which may be substituted or unsubstituted, saturated or unsaturated, linear, branched, cyclic or aromatic and the bridging group is a unsubstituted or substituted C3-C10 alkylene or C3-C10 alkoxy alkyl. Also disclosed is a nanoemulsion formulation which includes the ionic liquid compositions, at least one polymer, a hydrophobic liquid, an aqueous liquid, and a hydrophobic or hydrophilic therapeutic agent. Methods to deliver a therapeutic agent by delivering a nanoemulsion and methods to make a nanoemulsion are also disclosed.

Abstract: This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolytic cleavage can be used to release the drugs.

Abstract: The present disclosure relates to unimolecular core-shell nanoparticle, nanoclusters thereof, and platelet biomimetic nanoclusters thereof. The disclosed compositions are useful for treating a subject with a disease or condition, such as a cardiovascular disease. In a further aspect, the cardiovascular disease can be a vascular stenosis or restenosis. Also described herein are methods of making and using the unimolecular core-shell nanoparticle, nanoclusters thereof, and platelet biomimetic nanoclusters thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: The present invention relates to a pharmaceutical preparation containing an active ingredient and a release-controlling agent for adjusting the release of the active ingredient, in which the active ingredient is at least one selected from among mirabegron and a pharmaceutically acceptable salt thereof, and the release-controlling agent is a hydrogel-forming polymer, the hydrogel-forming polymer being at least one selected from among polyethylene oxide, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, and hydroxyethyl cellulose and having an average molecular weight ranging from 100,000 to 8,000,000. The present invention is capable of suppressing the generation of impurities therein and of effectively controlling the release of at least one selected from among mirabegron and a pharmaceutically acceptable salt thereof.

Abstract: Wiping compositions are disclosed well suited for destroying various different microorganism very quickly. The wiping composition contains a tertiary alkyl amine biocide in combination with one or more other components. The wiping composition, for instance, may contain a pH adjustor, chelating agent, one or more surfactants, and water as a liquid carrier. In one embodiment, the composition can be formulated to contain various organic solvents that increase efficacy against mycobacteria. The wiping composition is particularly well suited to being impregnated into a disposable wipe.

Abstract: Compositions and methods for skincare treatment are provided. The invention relates more generally to skin care treatment and more particularly, to compositions and methods for promoting healthy skin, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

Abstract: Compositions and methods for skincare treatment are provided. The invention relates more generally to skin care treatment and more particularly, to compositions and methods for promoting healthy skin, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

Abstract: Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine.

Abstract: An antibacterial device is disclosed that includes a substrate and an antibacterial coating or antibacterial surface being provided on at least a part of the substrate's surface. The antibacterial coating or surface includes Angstrom scale flakes, where the Angstrom scale flakes are arranged in a standing position on the substrate surface and are attached to the substrate surface via edge sides thereof. The Angstrom scale flakes can, for example, be graphene flakes, or graphite flakes having a thickness of a few atom layers. It has been found that such standing flakes are efficient in killing prokaryotic cells but do not harm eukaryotic cells.

Abstract: Disclosed herein is a method of alleviating symptoms of ocular surface discomfort, the method comprising: topically applying a cold slurry adjacent to a corneal limbus of an eye of a patient, wherein the cold slurry comprises water and a freezing point depressant, wherein the topical application of the cold slurry is configured to cause a degree of numbing of a cornea of the eye for a period of time, and wherein an ocular sensation of the eye is restored following the period of time.

Abstract: The subject of the application is protein hydrolyzates having specific amounts of the amino acids arginine and lysine, which demonstrate improved properties in hair treatment compositions and in cleansing compositions for skin and hair, and also enzymatic methods for the preparation thereof, and the cosmetic compositions comprising same.

Abstract: The present disclosure provides delivery systems for delivering FK506 locally to damaged nerve sites. Particulate FK506 incorporated into a fibrin gel, with the amount of FK506 sufficient to give an FK506 release rate over at least 14 days of at least 5 micrograms per milliliter of the treated tissue per day has been shown to remarkably improve axon regeneration. The delivery systems include particulate FK506 having sizes between about 500 microns to about 1 millimeter encapsulated in a fibrin matrix, powdered FK506 encapsulated within electrospun films, powdered FK506 encapsulated within a cellulose matrix, and a flexible film of small intestinal submucosa having a plurality of solid islands located on one side thereof, with each island containing a preselected amount of FK506 and a polyester.

Abstract: In a zinc oxide powder of the present invention, a content of a water-soluble substance is 0.30% by mass or less, and a mass ratio between an alkali metal and an alkaline earth metal which are included in the water-soluble substance is in a range of 1:2 to 10:1.

Abstract: Provided are transplant preservation solutions comprising a polyglycerol wherein the polyglycerol is of a molecular weight between about 0.15 kDa and about 3.99 kDa, methods and uses thereof as well as kits providing said transplant preservation solutions.

Abstract: Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.

Abstract: Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.

Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

Abstract: Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.

Abstract: An object of the present invention is to improve the hardness of the capsule film of a hard capsule. The present invention improves the hardness of the capsule film of a hard capsule by adding a starch decomposition product, and/or at least one clay mineral selected from the group consisting of talc, bentonite, and kaolin, to a hard capsule film.